[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-polycythemia-vera-myelofibrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-polycythemia-vera-myelofibrosis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,54,86,112,133,158,182,207,305,326,353],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100629072","phase-1-a-phase-1-study-of-prt12396-in-participants-with-select-myeloproliferative-neoplasms-100629072",false,"NCT07469891","A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms","A Phase 1, Open-Label, Multi-Center, Safety and Efficacy Study of PRT12396 in Participants With Polycythemia Vera and Myelofibrosis","Inclusion Criteria:\n\n* Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations (including contraception requirements), and other study procedures.\n* Confirmed diagnosis of PV or MF according to WHO 2016 or revised ICC\u002FWHO 2022 criteria\n* Documented presence of a JAK2 V617 mutation\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Estimate life expectancy of ≥12 weeks per investigator assessment.\n* Negative serum or urine pregnancy test and agree to use contraception or maintain true abstinence.\n* Adequate organ function and bone marrow reserves (hematology, renal, and hepatic)\n\nExclusion Criteria:\n\n* History of another malignancy within 3 years prior to enrollment, except for malignancy considered cured with low risk of recurrence.\n* Clinically significant anemia due to nutritional deficiency or hemolytic disorders.\n* Active or uncontrolled infection requiring systemic therapy or hospitalization.\n* Any other medical or psychiatric conditions that, in the Investigator's judgment, would increase risk or interfere with study participation or interpretation of results.\n* Clinically significant or uncontrolled medical conditions, including active infection or cardiovascular disease, that would increase risk or interfere with study participation.\n* Unresolved toxicity \\> Grade 1 from prior anticancer therapy, except for alopecia or peripheral neuropathy ≤ Grade 2.\n* Pregnancy or breastfeeding\n* Known sensitivity or contraindication to any component of study, or the excipients of study treatment.\n* Prior systemic therapy for PV or MF, prior or planned allogeneic hematopoietic stem-cell transplantation, recent major surgery, prior splenectomy or prior splenic irradiation, or use of hematopoietic growth factors within protocol-defined washout periods.\n* Use of strong or moderate cytochrome P450 (CYP) 3A4 inhibitor or inducer, sensitive CYP3A substrates with narrow therapeutic range, or acid-reducing agents that cannot be discontinued prior to study treatment.\n* Participation in another interventional clinical study.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE\\[s\\]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).",[26,27,28,29,30,31],"Polycythemia Vera (PV)","Myelofibrosis (MF)","Myeloproliferative Neoplasms (MPNs)","Post-Polycythemia Vera Myelofibrosis","Post-Essential Thrombocythemia Myelofibrosis","Primary Myelofibrosis (PMF)",[33,34,35,36,37,38,39,40],"High-Risk Polycythemia Vera (PV)","Intermediate-1 or Intermediate-2 Risk Primary MF","High-Risk Primary MF","Post-Polycythemia Vera MF","Post-Essential Thrombocythemia MF","PRT12396","JAK Inhibitor","Myeloproliferative Neoplasms (MPN)","RECRUITING","2026-07-30",{"date":44,"type":45},"2026-07-31","ACTUAL",{"date":47,"type":45},"2026-04-29",{"date":49,"type":20},"2028-04",{"name":51,"class":52},"Prelude Therapeutics","INDUSTRY",8,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":21,"phases":64,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100649316","phase-1-revumenib-in-patients-with-myelofibrosis-100649316","NCT07734077","Revumenib in Patients With Myelofibrosis","Phase Ib\u002FII Study Of Revumenib As Monotherapy Or In Combination With Jak Inhibitors In Patients With Myelofibrosis","MPN-RC 129","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Adults ≥ 18 years of age at time of signing the informed consent\n* Participants must voluntarily sign informed consent form (ICF) and be willing and able to adhere to the study visit schedule and all protocol requirements.\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Participants must have a pathologically confirmed diagnosis of PMF, post-ET-MF or post-PV-MF as per the WHO diagnostic criteria, with intermediate-1 or higher risk disease by DIPSS (14.1).\n* Criteria for COHORT-1 (Monotherapy): Treated with at least one prior line of JAK inhibitor therapy to which they were refractory\u002Fresistant, lost response, or intolerant, or is not a candidate for approved JAK inhibitor therapy per investigator judgement, and with one or more of the following features of active disease:\n\n  * Spleen palpable ≥ 5 cm below the left costal margin or \\> 450cm3 by MRI\u002FCT\n  * MPN-SAF TSS ≥ 10\n  * Transfusion dependence (requiring at least 6 units of PRBCs in the 12 weeks prior to study enrollment, for a hemoglobin \\\u003C 8.5g\u002FdL in the absence of bleeding or treatment-induced anemia)\n* Criteria for COHORT-2 (Combination therapy): Currently receiving treatment with an approved JAK inhibitor (including ruxolitinib, fedratinib, or momelotinib) with stable dose for at least 12 weeks prior to study enrollment, and with one or more of the following features of active disease:\n* Spleen palpable ≥ 5 cm below the left costal margin or \\> 450cm3 by MRI\u002FCT\n* MPN-SAF TSS ≥ 10\n* Transfusion dependence (requiring at least 6 units of PRBCs in the 12 weeks prior to study enrollment, for a hemoglobin \\\u003C 8.5g\u002FdL in the absence of bleeding or treatment-induced anemia)\n* Adequate organ function as demonstrated by the following within 28 days prior to Cycle 1 Day 1:\n\n  * ALT (SGPT) and\u002For AST (SGOT) \\\u003C 3 × the upper limit of normal (ULN), or \\\u003C 5 × ULN if, upon judgment of the treating physician, it is believed to be due to MF-related extramedullary hematopoiesis (EMH);\n  * Total bilirubin \\\u003C 3 × ULN for age (\\\u003C 4 x ULN for age if attributed to MF related EMH or Gilbert's syndrome)\n  * Creatinine clearance ≥ 30 mL\u002Fmin by Cockcroft Gault formula;\n  * Prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × upper limit of normal (ULN)\n  * Adequate cardiac function defined as ejection fraction of ≥50% by echocardiogram or multigated acquisition (MUGA) scan\n  * Bone marrow and\u002For peripheral blood blast count \\\u003C 10%;\n  * Absolute neutrophil count (ANC) ≥ 1000 mm3; and\n  * Platelet count ≥ 75 x 109\u002FL at time of enrollment\n* QTcF ≤ 450msec at screening\n* Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia\n* Life expectancy of at least six months\n* Females of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine or serum pregnancy test within 72 hours before the initiation of protocol therapy. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be obtained. Participants are considered to be not of childbearing potential if they are considered to be post-menopausal or surgically sterilized (eg, , hysterectomy, bilateral salpingectomy). Females who have been amenorrheic for at least 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, ovarian suppression or any other reversible reason.\n\n  * Females of childbearing potential must be willing to use a highly effective method of contraception from the time of first study intervention dose through the required contraceptive period (4 months following the last dose of study drug) and must be willing to refrain from in vitro fertilization and egg donation during the required contraceptive period.\n  * Males must be surgically sterile or agree to use barrier contraception (male condoms) from the time of first study intervention dose through the required contraceptive period of 4 months after last dose of study drug. Males must be willing to refrain from sperm donation during the required contraceptive period.\n* Able to adhere to the study visit schedule and all protocol requirements Exclusion Criteria\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Treatment with any MF-directed therapy (including investigational therapies) within 2 weeks or 5 half-lives, whichever is shorter, of Cycle 1 Day 1\n\n  * Participants in COHORT-1 should not have received a JAK inhibitor within 14 days prior to Cycle 1 Day 1. Participants who remain on JAK inhibitor at time of screening should be tapered off per investigator discretion.\n  * Hydroxyurea is permitted until the day prior to C1D1, if needed for disease control.\n* Undergone allogeneic hematopoietic stem cell transplant (allo-HSCT) within the last 6 months prior to enrollment, or with active GVHD and\u002For on immunosuppressive therapy.\n* Not currently a candidate for allo-HSCT, per investigator discretion. Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible.\n* Prior splenectomy, splenic irradiation, or splenic artery embolization within 6 months of C1D1\n* GI disease meeting any of the following criteria:\n\n  * Impairment of GI function that could significantly alter the absorption of revumenib (eg. Gastric bypass, gastroparesis)\n  * Cirrhosis with a Child-Pugh score of B or C, or National Cancer Institute (NCI) Organ Dysfunction Working Group category of Severe Dysfunction\n  * Inability to swallow oral medications\n* Any of the following cardiac abnormalities:\n\n  * Any of the following within the 6 months before study entry: myocardial infarction, uncontrolled\u002Funstable angina, congestive heart failure (New York Heart Association Class ≥II), life-threatening, uncontrolled arrhythmia, cerebrovascular accident or transient ischemic attack. Participants with controlled atrial fibrillation are allowed to enroll\n  * QTcF (Fridericia's correction) \\> 450ms at screening\n  * Diagnosis of suspicion of Long QT syndrome or family history of Long QT syndrome\n* Recipient of organ transplant\n* Other malignancy within the last three years, other than curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, organ-confined or treated non-metastatic prostate cancer with normal prostate-specific antigen, in situ breast carcinoma after complete surgical resection, or superficial\u002Fnon-invasive transitional cell bladder carcinoma.\n* Presence of uncontrolled active infection of any type. Mild to moderate localized infections under control with antibiotic treatment are acceptable for study entry. Patients with ongoing serious infection are not eligible regardless of antimicrobial therapy. Prophylactic antibiotics are acceptable per NCCN infection guidelines.\n* If participant is known to be human immunodeficiency virus (HIV)-positive, they must have an undetectable HIV viral load within the previous 6 months. If viral load testing has not been performed within the previous 6 months, it much be performed during screening.\n* Known active or chronic hepatitis B, or active hepatitis C infection. Participants with a history of HCV infection who have completed curative therapy for HCV at least 12 weeks before the Screening Visit and have a documented undetectable viral load at the Screening Visit are eligible for inclusion.\n* The following exclusions apply related to concomitant use of CYP3A4 inhibitors and inducers:\n\n  * Participants who will not receive revumenib with coadministration of a strong CYP3A4i (eg, itraconazole, ketoconazole, posaconazole, or voriconazole) must discontinue all strong CYP3A4 inhibitors at least 7 days or 5 half-lives, whichever is longer, before the first dose of revumenib. They will receive goal dose of revumenib 270 mg Q12h and they may continue to receive moderate or weak CYP3A4 inhibitors, including fluconazole and isavuconazole.\n  * Participants who will receive revumenib with coadministration of a strong CYP3A4i (eg, itraconazole, ketoconazole, posaconazole, or voriconazole) must have started the treatment at least 24 hours before the first dose of revumenib. They will receive goal dose of revumenib 160 mg Q12h.\n  * Concomitant use of a strong or moderate CYP3A4 inducer is prohibited while on study. Strong or moderate inducers of CYP3A4 should be discontinued at least five half-lives or 14 days (whichever is longer) prior to the first dose of revumenib.\n* Participants requiring the concurrent use of medications known or suspected to prolong the QT\u002FQTc interval, with the exception of drugs with low risk of QT\u002FQTc prolongation that are used as standard supportive therapies (eg, diphenhydramine, famotidine, ondansetron, sulfamethoxazole and trimethoprim) and the azoles permitted. Females who are pregnant or lactating.\n* Any serious, unstable medical or psychiatric condition that would prevent (as judged by the Investigator) the participant from signing the informed consent form or any condition, including the presence of laboratory abnormalities and inability to swallow pills, which places the participant at unacceptable risk if they were to participate in the study or confounds the ability to interpret data from the study.\n* Is or has an immediate family member (e.g., spouse, parent\u002Flegal guardian, sibling, or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective IRB approval (by chair or designee) is given allowing exception to this criterion for a specific participant.",{"count":63,"type":20},32,[23,65],"PHASE2","This is a Phase Ib\u002FII 2 study investigating the safety and efficacy of revumenib in two cohorts of participants with myelofibrosis. COHORT-1 will investigate the safety of revumenib as monotherapy in participants with myelofibrosis previously treated with a JAK inhibitor. Following confirmation of safety in COHORT-1, the study will proceed with enrollment in COHORT-2, which will evaluate the efficacy and safety of revumenib in combination with a JAK inhibitor.",[68,69,70],"Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis",[68,72,73],"Revumenib","JAK inhibitor","NOT_YET_RECRUITING","2026-07-24",{"date":77,"type":45},"2026-07-29",{"date":79,"type":20},"2026-12-01",{"date":81,"type":20},"2028-12-01",{"name":83,"class":84},"John Mascarenhas","OTHER",1,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":85},"100591168","research-platform-myelofibrosis-and-anemia-100591168","NCT06976918","Research Platform Myelofibrosis and Anemia","Clinical Research Platform on Treatment, Quality of Life and Outcome of Patients With Primary and Secondary Myelofibrosis and Anemia Who Are JAK Inhibitor Treatment-naïve or JAK Inhibitor Treatment-experienced (RHODOLITE)","RHODOLITE","Inclusion Criteria:\n\n* Confirmed diagnosis of primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) (Note: diagnosis according to WHO-2017, ICC-2022 or WHO-2022 or IWG-MRT criteria, respectively).\n* Diagnosis of anemia at the time of enrollment as per individual, clinical assessment by the local physician.\n* Start of first or subsequent systemic treatment for MF.\n* Informed consent and registration for the GSG-MPN Bioregistry.\n* Willingness and capability to participate in PRO assessment.\n* Signed and dated informed consent form for RHODOLITE at the latest six weeks after start of the respective systemic MF treatment.\n\nExclusion Criteria:\n\n* No systemic therapy for diagnosed primary or secondary MF.\n* Planned allogenic stem cell transplantation (allo-SCT) or active participation in an interventional clinical trial.",{"count":95,"type":20},200,"OBSERVATIONAL","The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor research platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease and to collect patient-reported outcomes for patients with primary and secondary myelofibrosis and anemia in Germany.",[99,100,69,70,101,102,68],"Primary Myelofibrosis","Secondary Myelofibrosis","Anemia","Myelofibrosis; Anemia","2026-06-03",{"date":105,"type":45},"2026-06-05",{"date":107,"type":45},"2026-02-19",{"date":109,"type":20},"2031-09",{"name":111,"class":52},"iOMEDICO AG",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":85},"100541226","phase-1-open-label-phase-12-study-of-tasquinimod-in-patients-with-primary-myelofibrosis-pmf-post-polycythemia-vera-myelofibrosis-post-pv-mf-or-post-essential-thrombocytosis-myelofibrosis-post-et-mf-100541226","NCT06327100","Open Label Phase 1\u002F2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)","Inclusion Criteria:\n\nParticipants eligible for inclusion in this study have to meet the following criteria:\n\nMyelofibrosis MF Monotherapy:\n\nParticipants who are not candidates for, intolerant of, or relapsed\u002Frefractory to approved JAKi (ruxolitinib and \u002F or fedratinib \u002F pacritinib) or when further benefit from therapy is not anticipated per investigator. Participants not eligible for JAKi therapy irrespectively of previous treatments. Prior JAKi therapy is not required.\n\nMyelofibrosis Ruxolitinib Combination MF participants treated with Ruxolitinib for at least 3 months on a stable, uninterrupted dose for at least 2 months prior to study enrollment AND have suboptimal response (palpable spleen of ≥5 cm, or total symptoms score of ≥10) or progressive anemia\u002Fthrombocytopenia\u002Fneutropenia.\n\nAND all the below criteria in both cohorts:\n\n* Must be diagnosed with treatment requiring PMF or post ET\u002FPV MF diagnosed according to the 2016 World Health Organization with intermediate -1, intermediate -2 or high-risk disease according to the DIPSS prognostic scoring system, or if with low risk disease then with symptomatic splenomegaly that is ≥ 5 cm below left costal margin by physical exam.\n* Peripheral or bone marrow blasts must be \\\u003C 10%\n* Participants must provide written informed consent.\n* Age 18 years or older. Because no dosing or adverse event data are currently available on the use of tasquinimod as monotherapy or in combination with ruxolitinib in patients \\\u003C18 years of age, children are excluded from this study.\n* Willing and able to comply with scheduled visits, treatment plan and laboratory tests.\n* Participant is able to swallow and retain oral medication.\n* ECOG performance status 0-2.\n* Required baseline laboratory status:\n\n  * Absolute neutrophil count (ANC) ≥ 1.0 x 109\u002FL (1000\u002Fmm3)\n  * Serum direct bilirubin ≤ 1.0 x ULN (upper limit of normal)\n  * AST (SGOT) or ALT (SGPT) \\[if both measured, then this applies to both measurements\\] ≤ 2.5 x ULN, except for participants with MF involvement of the liver who must have levels ≤ 5 x ULN\n  * Glomerular Filtration Rate (GFR) of ≥ 30 ml\u002Fmin based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation using serum or plasma creatinine or cystatin-C.\n* Treatment-related toxicities from prior therapies must have resolved to Grade ≤ 1.\n* At least 2 weeks from prior investigational MF-directed treatment (till the start of study drug). This excludes concurrent ruxolitinib which is allowed in combination cohort. Hydroxyurea is allowed as standard cytoreductive therapy up until one day prior to initiation of therapy with tasquinimod. No other standard of care therapy for MF is allowed (as specified in the exclusion criteria)\n* For women of childbearing potential, a documented negative serum or urine pregnancy test within 14 days prior to the administration of study drug.\n* The effects of tasquinimod on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female participants, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:\n\n  * Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n  * History of hysterectomy or bilateral salpingo-oophorectomy.\n  * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n  * History of bilateral tubal ligation or another surgical sterilization procedure.\n* Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of tasquinimod administration.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\nParticipants eligible for this study must not meet any of the following criteria:\n\n* Any concurrent severe and\u002For uncontrolled medical conditions that could increase the participant's risk for toxicity while in the study or that could confound discrimination between disease- and study treatment-related toxicities.\n* Impaired cardiac function or clinically significant cardiac diseases, including any of the following:\n\n  * History or presence of ventricular tachyarrhythmia.\n  * Presence of unstable atrial fibrillation (ventricular response \\> 100 bpm); Participants with stable atrial fibrillation are eligible, provided they do not meet any of the other cardiac exclusion criteria.\n  * Clinically significant resting bradycardia (\\\u003C 50 bpm).\n  * Angina pectoris or acute myocardial infarction ≤ 3 months prior to starting study drug.\n  * Other clinically significant heart disease (e.g., symptomatic congestive heart failure; uncontrolled arrhythmia or hypertension; history of labile hypertension or poor compliance with an antihypertensive regimen).\n* Participants who are currently receiving chronic (\\> 14 days) treatment with corticosteroids at a dose ≥ 10 mg of prednisone (or its glucocorticoid equivalent) per day, or any other chronic immunosuppressive treatment that cannot be discontinued prior to starting study drug.\n* Treatment with chemotherapy (except hydroxyurea within 1 day prior to study treatment), immunomodulatory drug therapy (e.g. thalidomide, interferon-alpha), platelet-reducing therapy (e.g. anagrelide), immunosuppressive therapy, and erythropoetin use within 28 days prior to study treatment\n* Treatment with experimental therapy within the past 2 weeks or 5 half-lives, whichever is shorter\n* Treatment with tasquinimod at any time\n* Participants with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of tasquinimod as per physician opinion\n* Participants with known or active (acute and chronic) Hepatitis A, B, or C; and Hepatitis B and C carriers, HIV. Participants are excluded regardless of detectability of viral load (lack of safety data).\n* Participants with clinically significant bacterial, fungal, parasitic or viral infection which require therapy\n* History of pancreatitis\n* History of malabsorption or other condition that would interfere with absorption of study drugs (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection)\n* Systemic treatment within 14 days prior to the initiation of study treatment with any of the following moderate or strong inhibitor, or moderate or strong inducer of cytochrome P-3A4 (CYP3A4): imidazoles (e.g. ketoconazole), protease inhibitors (e.g. ritonavir), macrolides (e.g. erythromycin), rifampicin, rifabutin, phenytoin, carbamazepine, St. John's wort.\n* Need for ongoing therapy with any of the following drug substances of narrow therapeutic range that are metabolized mainly by CYP3A4: alfentanil, fentanyl, quinidine, astemizole, terfenadine, sirolimus, tacrolimus, cyclosporine, cisapride, and ergotamine\n* Need for ongoing therapy with any of the following drug substances of narrow therapeutic range metabolized mainly by CYP1A2: duloxetine, palonosetron, theophylline, tizanidine, and ondansetron.\n* Need for ongoing therapy with any of the following drug substances of narrow therapeutic range metabolized mainly by CYP2D6: Dosulepin, Flecainide, Sotalol, Pimozide, Procainamide, Clonidine, Desipramine, Clomipramine, Amitriptyline, Imipramine, Nortriptyline, Trimipramine, Amoxapine, Dronedarone, Phenytoin\n* Ongoing treatment with warfarin, unless the INR is \\\u003C=3.0.\n* Known hypersensitivity to tasquinimod or any excipients in the study treatments\n* Any other condition that would, in the Investigator's judgment, contraindicate subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures\n* Prior inclusion in this study\n* Pregnant women are excluded from this study because tasquinimod is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with tasquinimod, breastfeeding should be discontinued if the mother is treated with tasquinimod. These potential risks may also apply to other agents used in this study.",{"count":119,"type":20},33,[23,65],"To learn if tasquinimod either alone or in combination with ruxolitinib can help to control PMF, post-PV MF, or post-ET MF.",[99,69,123],"Post-Essential Thrombocytosis Myelofibrosis","2026-05-21",{"date":126,"type":45},"2026-05-26",{"date":128,"type":45},"2024-08-01",{"date":130,"type":20},"2031-05-01",{"name":132,"class":84},"M.D. Anderson Cancer Center",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":21,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":157},"100542510","phase-1-a-phase-1-study-of-aj1-11095-in-patients-with-primary-myelofibrosis-pmf-post-polycythemia-vera-myelofibrosis-ppv-mf-or-post-essential-thrombocythemia-myelofibrosis-pet-mf-who-have-been-failed-by-a-type-i-jak2-inhibitor-jak2i-100542510","NCT06343805","A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)","A Multicenter, Open-Label, Phase 1 Study of AJ1-11095 Administered as Oral Monotherapy in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)","Inclusion Criteria:\n\n1. 18 years of age or older.\n2. Diagnosis of PMF, post-PV MF, or post-ET MF.\n3. DIPSS Intermediate-2 or High-risk MF with ≤10% blasts, regardless of JAK2 mutation status.\n4. Estimated spleen volume ≥450cm3.\n5. MFSAF v.4.0 TSS ≥10, or at least 2 of 7 MFSAF-assessed symptoms with scores ≥3.\n6. ECOG PS of 0, 1, 2, or 3.\n7. Prior therapy with at least 1 type I JAK2 inhibitor, and either failed to achieve a response or relapsed after achieving a response.\n8. ANC ≥1.0×10\\^9\u002FL.\n9. Platelet count ≥75×10\\^9\u002FL.\n10. eGFR ≥45 mL\u002Fmin\u002F1.73m2.\n11. Serum total bilirubin ≤2.0 × upper limit of normal (ULN).\n12. AST and ALT ≤3.0 × ULN.\n13. QTcF ≤480 msec.\n\nExclusion Criteria:\n\n1. Prior splenectomy.\n2. Splenic irradiation within 3 months prior to first dose of study drug.\n3. Ongoing use of systemic corticosteroids at dose equivalent to \\>10mg\u002Fday of prednisone.\n4. Uncontrolled intercurrent illness such as an acute infection.\n5. Chronic active or acute hepatitis B or C infection.\n6. Chemotherapy in the previous 4 weeks prior to first dose of study drug (Hydrea is permitted until 5 days before starting protocol therapy).\n7. Use of a Type I JAK2 inhibitor must have been discontinued for at least 5 days or 5 half-lives prior to dosing (whichever is longer).\n8. Use of erythropoiesis stimulating agents (unless stable for \\>8 weeks).\n9. Peripheral neuropathy ≥ Grade 2 (NCI CTCAE v 5.0).\n10. Unable or unwilling to undergo CT or MRI for spleen size imaging.\n11. Pregnant or breastfeeding.\n12. Requirement for therapy with a medication that is a strong CYP3A4 inhibitor as a concomitant medication.",{"count":141,"type":20},76,[23],"AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and changes in biomarkers of an orally administered type II JAK2 inhibitor, AJ1-11095, in subjects with primary or secondary myelofibrosis previously treated with at least one type I JAK2 inhibitor.",[99,30,29,145,146,147],"PMF","PPV-MF","PET-MF","2026-05-08",{"date":150,"type":45},"2026-05-12",{"date":152,"type":45},"2024-10-23",{"date":154,"type":20},"2027-02-15",{"name":156,"class":52},"Ajax Therapeutics, Inc.",21,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":21,"phases":167,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":157},"100543112","phase-3-a-study-to-evaluate-safety-and-efficacy-of-bomedemstat-mk-3543-017-100543112","NCT06351631","A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)","A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study","Inclusion Criteria:\n\n* Is from a bomedemstat study sponsored by Imago BioSciences, Inc. (a subsidiary of Merck \\& Co., Inc.) or MSD, and established by the Sponsor as MK-3543-017 ready\n* Has received at least 6 months of treatment with bomedemstat in the IMG-7289-202\u002FMK-3543-005 study, while safely tolerating bomedemstat, and receiving clinical benefit from its use in the estimation of the investigator\n* ET and PV participants from established feeder studies other than IMG-7289- 202\u002FMK-3543-005 must have achieved confirmed hematologic remission, must be safely tolerating bomedemstat, and must be receiving clinical benefit from its use in the estimation of the investigator\n* Is not currently on a dose hold\n* Participant must be able to swallow oral medication and follow instructions for at-home dosing of bomedemstat\n\nExclusion Criteria:\n\n* Has received prohibited concomitant medications\n* Ongoing or planned participation in another investigational study\n* Has noncompliance in prior bomedemstat study receiving \\\u003C90% of assigned doses excluding suspensions or holds as assigned by the investigator",{"count":166,"type":20},400,[168],"PHASE3","The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria:\n\n* Participants from the IMG-7289-202\u002FMK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat;\n* Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202\u002FMK-3543-005 must have achieved confirmed hematologic remission.\n\nNo hypothesis testing will be conducted in this study.",[171,99,68,69,70,172],"Thrombocythemia, Essential","Polycythemia Vera","2026-04-01",{"date":175,"type":45},"2026-04-02",{"date":177,"type":45},"2024-05-23",{"date":179,"type":20},"2034-12-04",{"name":181,"class":52},"Merck Sharp & Dohme LLC",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":191,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":206},"100627375","phase-2-selinexor-and-pacritinib-in-jak-inhibitor-nave-mf-patients-with-cytopenias-100627375","NCT07447817","Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias","Investigator-Initiated, Open-Label, Phase II Trial of Selinexor in Combination With Pacritinib in Patients With Myelofibrosis Who Are JAK Inhibitor-Naïve and Have Cytopenias (ILLUMINATE)","Inclusion Criteria:\n\n* Adults ≥ 18 years of age capable of providing informed consent\n* Pathologically confirmed diagnosis of PMF, post-ET MF, or post-PV MF as per the World Health Organization (WHO) diagnostic criteria - Intermediate-1, Intermediate-2, or High-Risk disease by the Dynamic International Prognostic Scoring System (DIPSS)\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Baseline splenomegaly ≥ 5cm palpable below the left costal margin and in the midclavicular line OR ≥ 450cc by imaging (i.e. ultrasound, CT, MRI)\n* Baseline anemia, defined by hemoglobin \\\u003C 10 g\u002FdL within 28 days prior to Cycle 1 Day 1\n* Baseline thrombocytopenia, defined by platelet count 50-150 x 109\u002FL without platelet transfusions within 28 days prior to Cycle 1 Day 1\n* Adequate organ function as demonstrated by the following within 28 days prior to Cycle 1 Day 1:\n\n  * ALT (SGPT) and\u002For AST (SGOT) ≤ 3x the upper limit of normal (ULN), or ≤ 4 x ULN if, upon judgment of the treating physician, it is believed to be due to MF-related extramedullary hematopoiesis (EMH);\n  * Direct bilirubin ≤ 1.5 x ULN; or ≤ 2x ULN if, upon judgment of the treating physician, it is believed to be due to MF-related extramedullary hematopoiesis (EMH) or documented Gilbert's syndrome;\n  * Creatinine clearance ≥ 30 mL\u002Fmin;\n  * Prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (Exceptions to coagulation parameters may be considered for patients who are taking concomitant anticoagulation medications or have a documented anti-phospholipid antibody, after discussion with Study Chair approval)\n  * Bone marrow and\u002For peripheral blood blast count \\\u003C 5%; and\n  * Absolute neutrophil count (ANC) ≥ 1500 mm3 without need for growth factors within 7 days prior to Cycle 1 Day 1.\n* Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia\n* Life expectancy of at least six months\n* Patients with active hepatitis B virus are eligible if antiviral therapy for hepatitis B has been given for \\>8 weeks and the viral load is \\\u003C100 IU\u002FmL.\n* Patients with history of hepatitis C virus (HCV) are eligible if they have received adequate curative anti-HCV treatment and HCV viral load is below the limit of quantification.\n* Patients with history of human immunodeficiency virus are eligible if they have cluster of differentiation (CD)4+ T-cell counts ≥350 cells\u002FμL, negative viral load, and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections in the last year and should be on established antiretroviral therapy for at least 4 weeks.\n* Women of childbearing potential (WOCBP) and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Men must agree to use a condom and not father a child or donate sperm for the duration of the study and for 90 days after the last dose of study therapy\n* Able to adhere to the study visit schedule and all protocol requirements\n\nExclusion Criteria:\n\n* Prior treatment with Janus kinase (JAK) inhibitors\n* Prior treatment with selinexor or other Exportin 1 (XPO1) inhibitors\n* Treatment with any MF-directed therapy (including investigational therapies and excluding hydroxyurea) within 2 weeks or 5.5 half-lives, whichever is shorter, of Cycle 1 Day 1\n* Completed hematopoietic cell transplant (HCT)\n* Prior splenectomy, splenic irradiation, or splenic artery embolization within 6 months of Cycle 1 Day 1\n* Impairment of gastrointestinal (GI) function or GI disease that could significantly alter the absorption of pacritinib or selinexor, including any unresolved nausea, vomiting, or diarrhea \\> National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v6.0 Grade 1\n* Uncontrolled or currently progressing ocular toxicities\n* Moderate or severe cardiovascular disease meeting one or both of the below criteria:\n\n  * Presence of cardiac disease, including a myocardial infarction within 6 months prior to study entry, unstable angina pectoris, New York Heart Association Class III\u002FIV congestive heart failure, or uncontrolled hypertension\n  * Documented major electrocardiogram (ECG) abnormalities (not responding to medical treatments)\n* Grade 2 or greater bleeding event within the past 6 months\n* QT corrected by the Fridericia method (QTcF) prolongation \\> 480 ms or other factors that increase the risk for QT interval prolongation (eg, hypokalemia \\[defined as serum potassium \\\u003C 3.0 mEq\u002FL that is persistent and refractory to correction\\], or history of long QT interval syndrome)\n* Recipient of organ transplant\n* History of major surgery or any planned surgical procedures within 28 days prior to Cycle 1 Day 1\n* Other malignancy within the last three years, other than curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, organ-confined or treated non-metastatic prostate cancer with normal prostate-specific antigen, in situ breast carcinoma after complete surgical resection, or superficial\u002Fnon-invasive transitional cell bladder carcinoma.\n* Presence of active serious infection\n* Use of any prohibited medications (5.8) within two weeks or five half-lives, whichever is longer, prior to Cycle 1 Day 1\n* Women who are pregnant or lactating\n* Any serious, unstable medical or psychiatric condition that would prevent (as judged by the Investigator) the subject from signing the informed consent form (ICF) or any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if they were to participate in the study or confounds the ability to interpret data from the study\n* Is or has an immediate family member (e.g., spouse, parent\u002Flegal guardian, sibling, or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective IRB approval (by chair or designee) is given allowing exception to this criterion for a specific subject",{"count":190,"type":20},26,[65],"This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.",[68,69,70],[68,101,195,196,197],"Thrombocytopenia","Pacritinib","Selinexor","2026-03-16",{"date":200,"type":45},"2026-03-18",{"date":202,"type":20},"2026-05-04",{"date":204,"type":20},"2030-05-24",{"name":83,"class":84},3,{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":216,"conditions":217,"keywords":263,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":304},"100620792","mpn-progression-registry-observational-study-tracking-symptoms-treatments-and-disease-progression-in-people-with-myeloproliferative-neoplasms-mpns-100620792","NCT07362225","MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","The MPN PROGRESSion Registry: A Retrospective and Prospective Observational Study Collecting Patient-Reported Outcomes, Electronic Health Records, and Claims Data to Track Symptoms, Treatments, and Disease Progression in Individuals Diagnosed With Myeloproliferative Neoplasms (MPNs).","Inclusion Criteria:\n\n* Adults aged 18 years or older at the time of enrollment.\n* Confirmed diagnosis of a myeloproliferative neoplasm (MPN), including one or more of the following subtypes, according to WHO 2022 criteria, including patients originally diagnosed with one of these conditions but who have received one or more stem cell transplants (SCTs) or bone marrow transplants (BMTs):\n* Polycythemia vera (PV)\n* Essential thrombocythemia (ET)\n* Primary myelofibrosis (PMF)\n* Secondary myelofibrosis (post-ET or post-PV MF)\n* Pre-fibrotic primary myelofibrosis (pre-PMF)\n* Myeloproliferative neoplasm-unclassifiable (MPN-U)\n* Myeloproliferative neoplasm, accelerated phase (MPN-AP)\n* Myeloproliferative neoplasm, blast phase (MPN-BP)\n* Post-MPN acute myeloid leukemia (AML)\n* Myelodysplastic syndrome (MDS)\u002FMPN overlap syndrome\n* Myeloproliferative neoplasm, blast phase (MPN-BP)\n* Ability to provide informed consent electronically or through a legally authorized representative.\n* Willingness to share health information, including electronic health records (EHR), laboratory values, and survey responses.\n* Willingness to complete periodic patient-reported outcome (PRO) surveys and symptom tracking assessments.\n\nExclusion Criteria:\n\n* Individuals under 18 years of age.\n* Inability to provide informed consent, either directly or through a legally authorized representative.\n* Currently enrolled in an interventional clinical trial where participation would interfere with the ability to participate in this observational registry (based on investigator or sponsor judgment).\n* Any condition that, in the judgment of the study team, would make participation in the registry infeasible or unsafe.",{"count":215,"type":20},5000,"The MPN PROGRESSion Registry is a multi-year, observational research study designed to improve understanding of myeloproliferative neoplasms (MPNs)-a group of rare, chronic blood cancers that include polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (MF), pre-fibrotic primary myelofibrosis (pre-PMF), secondary myelofibrosis, myeloproliferative neoplasm-unclassifiable (MPN-U), MPN in accelerated phase (MPN-AP), and MPN in blast phase (MPN-BP), post-MPN Acute Myeloid Leukemia (AML), and MDS\u002FMPN overlap syndrome as defined above per WHO 2022 criteria, including patients originally diagnosed with one of these conditions but who have received one or more SCTs and\u002For BMTs . These conditions are characterized by abnormal blood cell production in the bone marrow and may lead to complications such as blood clots, bleeding, bone marrow fibrosis, and, in some cases, progression to acute leukemia.\n\nThe central hypothesis of the registry is that collecting and analyzing real-world, longitudinal data-including electronic health records (EHRs), laboratory values, treatments, and patient-reported outcomes (PROs)-from a diverse population of people living with MPNs will help identify patterns and predictors of disease progression, treatment response, quality of life, and long-term outcomes. These insights are intended to guide future research, inform clinical guidelines, and support improvements in patient care.\n\nThe registry is non-interventional and observational; participants do not receive investigational treatments, and all medical care continues under the supervision of their own physicians. Data collection includes EHRs, PRO surveys, patient-reported symptom and lab tracking, insurance claims, and, in the future, may include linkages with other relevant disease registries and datasets. Potential collaborations under consideration include those with the European LeukemiaNet (ELN) MPN Registry, the Mayo Clinic MPN Database, the Center for International Blood and Marrow Transplant Research (CIBMTR), the SEER Program, Harmony Alliance Foundation, and the National Cancer Database (NCDB).\n\nThe registry emphasizes the patient voice, incorporating lived experiences related to hallmark MPN symptoms such as fatigue, pruritus (itching), bone pain, night sweats, and social and emotional impacts. Participants will be followed for at least five years, with many enrolled for ten years or longer, to capture the natural history of disease and long-term outcomes. PRO surveys will be completed approximately every six months, and EHR data will be regularly reviewed to track changes in clinical status, treatment, and disease evolution.\n\nStatistical analyses will use descriptive and inferential methods to examine clinical characteristics, symptom burden, disease trajectories, and patient-centered outcomes. Planned subgroup analyses may compare differences across diagnoses, treatment approaches, demographics, or genomic factors. Analytic plans will be finalized during the course of the study and may evolve in response to emerging scientific questions.\n\nThe registry is open to adults (18 years or older) living in the United States who have been diagnosed with any of the included MPN subtypes and are willing to share health information and complete study surveys. Individuals currently enrolled in interventional clinical trials or unable to provide informed consent may be excluded. Participation is voluntary, and participants may withdraw from the study at any time without affecting their medical care.\n\nPrivacy and data security are core priorities. Participant data will be securely stored and managed in accordance with all applicable privacy laws and research regulations. No identifiable information will be shared with external parties without appropriate authorization. Oversight is provided by a Steering Committee and a Patient Engagement Advisory Committee (PEAC), ensuring rigorous scientific, ethical, and patient-centered governance.\n\nThe registry is sponsored by the MPN Research Foundation, a nonprofit organization advancing research and patient advocacy in myeloproliferative neoplasms (MPNs). Participants can contact the registry team at any time with questions and will receive periodic updates on study findings.\n\nThis study aims to address critical gaps in understanding the real-world experiences of people with MPNs-such as symptom burden over time, risk factors for progression, and how different treatments impact patient outcomes. Findings may inform clinical trial design, support biomarker discovery, and contribute to the development of updated treatment recommendations. The registry is committed to including participants from diverse backgrounds and clinical settings to ensure findings are broadly applicable across the MPN community. Summary results will be shared through scientific publications, presentations, and other dissemination efforts to advance MPN research and care globally.",[172,218,26,219,220,31,68,27,221,222,223,224,225,226,227,228,229,230,100,231,232,29,233,234,235,236,30,237,238,239,240,241,242,243,244,28,245,246,247,248,249,250,251,252,253,254,255,256,257,171,258,259,260,261,262],"ET (Essential Thrombocythemia)","Essential Thrombocythemia (ET)","Primary Myelofibrosis (MF)","Myelofibrosis, Primary","Myelofibrosis, Post ET","Myelofibrosis, Post PV","Myelofibrosis (PMF)","Myelofibrosis，MF","Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis","Myelofibrosis Due to and Following Polycythemia Vera","Myelofibrosis Transformation in Essential Thrombocythemia","Myelofibrosis With High Molecular Risk Mutations","MF","Secondary Myelofibrosis in Myeloproliferative Disease","Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)","Post-polycythemia Vera Myelofibrosis (PPV-MF)","Post-polycythemia Vera Myelofibrosis (Post-PV MF)","Post-polycythemia Vera Myelofibrosis(Post-PV MF)","Post-PV MF","Post-essential Thrombocythemia Myelofibrosis (PET-MF)","Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)","Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)","Post-ET MF","Pre-fibrotic Myelofibrosis","Myeloproliferative Disorder","Myeloproliferative Disorders","Myeloproliferative Disorders (MPD)","Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis","Myeloproliferative Neoplasm With 10% Blasts or Higher","Myeloproliferative Neoplasms","MPN","MPN (Myeloproliferative Neoplasms)","MPN-associated Myelofibrosis","Myeloproliferative Neoplasm, Unclassifiable","Myeloproliferative Neoplasm, Not Otherwise Specified","Accelerated Phase MPN","Accelerated Phase Myeloproliferative Neoplasm","Blast Phase MPN","Blast Phase Myeloproliferative Neoplasm","Thrombocythemia Myelofibrosis (PET-MF)","Thrombocythemia, Hemorrhagic","Agnogenic Myeloid Metaplasia","Chronic Idiopathic Myelofibrosis","Idiopathic Myelofibrosis","MDS\u002FMPN Crossover Syndromes",[247,172,264,100,265,242,251,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294],"Essential Thrombocythemia","Pre-fibrotic Primary Myelofibrosis","Myeloproliferative Neoplasm, Accelerated Phase","Myeloproliferative Neoplasm, Blast Phase","Chronic Myeloproliferative Disease","Hematologic Neoplasms","Bone Marrow Neoplasms","Blood Cancer","Disease Progression","Biomarker Discovery","Patient-Reported Outcomes","Electronic Health Records","Real-World Evidence","Longitudinal Study","Observational Study","Registry Study","Natural History Study","Quality of Life","Rare Diseases","Chronic Hematologic Diseases","Risk Stratification","Symptom Burden","Medical Claims Data","Longitudinal Data Collection","Patient-Centered Research","Health Outcomes Research","Clinical Outcomes","Clinical Guidelines Development","Regulatory Science","Drug Development","Treatment Response","2026-01-15",{"date":297,"type":45},"2026-01-23",{"date":299,"type":45},"2025-09-26",{"date":301,"type":20},"2035-09-08",{"name":303,"class":84},"MPN Research Foundation",2,{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":16,"minAge":312,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":206},"100521765","a-post-marketing-surveillance-study-to-assess-the-safety-of-fedratinib-in-korean-patients-with-myelofibrosis-100521765","NCT06073847","A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis","Inrebic® (Fedratinib) Post-Marketing Surveillance in Korean Patients With Myelofibrosis","Inclusion Criteria:\n\n* Participants 19 years of age or older\n* Participants who will receive fedratinib according to the approved label\n* For the first 2 years after marketing authorization, all participants who have received or are receiving fedratinib will also be registered\n* Participants who signed the informed consent form\n\nExclusion Criteria:\n\n* Participants who have been prescribed fedratinib for an indication not approved in Korea\n* Participants who have been prescribed fedratinib at a dose not approved in Korea\n* Participants for whom fedratinib is contraindicated as clarified in Korean prescribing information approved by the Ministry of Food and Drug Safety","19 Years",{"count":314,"type":20},137,"The purpose of this study is to assess the real-world safety of fedratinib for the treatment of adult participants with primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), or post essential thrombocythemia myelofibrosis (post-ET MF) who were previously treated with ruxolitinib. Participants will represent the overall patient population with PMF, post-PV MF or post-ET MF who lost adequate response to and\u002For are intolerant to ruxolitinib. Inadequate response definitions will follow Ministry of Food and Drug Safety-approved label and reimbursement criteria of the Health Insurance Review \\& Assessment Service.",[99,69,70],"2024-11-05",{"date":319,"type":45},"2024-11-06",{"date":321,"type":45},"2023-06-13",{"date":323,"type":20},"2027-12-20",{"name":325,"class":52},"Bristol-Myers Squibb",{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":21,"phases":335,"briefSummary":336,"conditions":337,"keywords":340,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":85},"100532885","phase-1-pacritinib-w-talazoparib-in-pts-w-myeloproliferative-neoplasms-unresponsive-to-jak2-inhibition-100532885","NCT06218628","Pacritinib w\u002F Talazoparib in Pts w\u002F Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition","Phase I Study Accessing the Safety of Pacritinib in Combination With Talazoparib in Patients With Myeloproliferative Neoplasms Unresponsive to Frontline JAK2 (Janus Kinase 2) Inhibition","Inclusion Criteria:\n\n* Patients must have histologically or cytologically confirmed primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF), post-essential thrombocythemia-myelofibrosis (PET-MF), chronic myelomonocytic leukemia, polycythemia vera, or essential thrombocytosis according to the 2008 World Health Organization criteria\n* Subject has at least 2 symptoms with a score ≥ 3 or a total score of ≥ 12, as measured by the MFSAF(Myelofibrosis Symptom Assessment Form) v4.0\n* Subject classified as intermediate-2 or high-risk MF, as defined by the Dynamic International Prognostic Scoring System Plus (DIPSS+70).\n* Age \\> 18 years.\n* ECOG (Eastern Cooperative Oncology Group) performance status 0-2\n* Subject must have received prior treatment with a single JAK2 inhibitor 4.1.6 for at least 12 weeks with documented disease progression OR subject must have appearance of new splenomegaly that is palpable to at least 5 cm below the left costal margin (LCM) in subjects with no evidence of splenomegaly prior to the initiation of any first line JAK2 inhibitor\n* Baseline QTc (corrected QT interval) \\\u003C0.47 seconds (Bazett formula)\n* Patients must have normal organ function as defined in protocol.\n* Ability to understand and willingness to sign a written informed consent and HIPAA consent document\n\nExclusion Criteria:\n\n* Patients may not be receiving any other investigational agents\n* Subjects must not be experiencing toxicity due to prior therapy that has not resolved to ≤Grade 1 by study registration, with the exception of sensory neuropathy related to previous systemic therapy exposure, alopecia and fatigue.\n* Patients that have transformed to Acute Myeloid Leukemia defined by \\>20% blasts count on peripheral blood smear or bone marrow biopsy evaluation\n* Uncontrolled inter-current illness including, but not limited to, any other malignancy (with the exception of hormonal therapy for breast cancer\u002Fprostate cancer in remission \\>1 year and for non-hormonal therapies for other cancers in remission for \\>3 years), other ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Patients with history of hemorrhagic stroke and evidence of uncontrolled bleeding as well as bleeding disorder\n* Known HIV positive patients on combination antiretroviral therapy are ineligible because these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.\n* Pregnant or breast-feeding.",{"count":334,"type":20},24,[23],"This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with standard of care dosing of pacritinib.",[99,69,70,338,172,339],"Chronic Myelomonocytic Leukemia","Essential Thrombocytosis",[341,196,342,343],"Talazoparib","JAK2 Inhibition","Myeloproliferative Neoplasm","2024-05-02",{"date":346,"type":45},"2024-05-03",{"date":348,"type":45},"2024-04-05",{"date":350,"type":20},"2030-08-27",{"name":352,"class":84},"Fox Chase Cancer Center",{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":360,"targetDuration":362,"studyType":96,"phases":4,"briefSummary":363,"conditions":364,"keywords":367,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":85},"100507083","asian-myeloproliferative-neoplasm-mpn-registry-100507083","NCT05882773","Asian Myeloproliferative Neoplasm (MPN) Registry","Asian Myeloproliferative Neoplasm (MPN) Registry - An Asian Myeloid Working Group (AMWG) Project.","Inclusion Criteria:\n\n1. Age ≥ 18 years old at the time of diagnosis of MPN.\n2. Subject was diagnosed with one of the following disorders according to the 2017 WHO classification (for patients diagnosed before 2017, the bone marrow reports will be re-evaluated according to the 2017 WHO classification):\n\n   1. Polycythaemia vera\n   2. Essential thrombocythemia\n   3. Primary myelofibrosis, pre-fibrotic\u002Fearly stage\n   4. Primary myelofibrosis, overt fibrotic stage\n   5. Post-polycythaemia vera myelofibrosis\n   6. Post-essential thrombocythaemia myelofibrosis\n   7. MPN-unclassifiable\n3. All subjects need to provide informed consent.\n\nExclusion Criteria:\n\nA subject will not be eligible if he\u002Fshe meets any of the following criteria:\n\n1\\. Subject was diagnosed with myelodysplastic syndrome, myelodysplastic syndrome\u002Fmyeloproliferative neoplasm, or chronic myeloid leukaemia BCR-ABL1 positive, under the 2017 WHO classification",{"count":361,"type":20},1000,"10 Years","This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.",[343,172,264,69,70,99,365,366],"Primary Myelofibrosis, Prefibrotic Stage","Primary Myelofibrosis, Fibrotic Stage",[368,369,370,371],"Myeloproliferative neoplasm","Epidemiology","Outcome","Prognostic factors","2023-05-21",{"date":374,"type":45},"2023-05-31",{"date":376,"type":20},"2023-05",{"date":378,"type":20},"2026-12",{"name":380,"class":84},"The University of Hong Kong"]